Peter E. Clark, MD

Same author

Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

European urology·2026

Same author

Racial and socioeconomic disparities from time of diagnosis to treatment for small renal masses.

BJUI compass·2026

Same author

Protocol-driven same day discharge for robotic radical prostatectomy.

Urologic oncology·2025

Same author

Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort.

Urologic oncology·2024

Same author

Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.

Scientific reports·2024

Same author

Reply by Authors.

Urology practice·2024

Same journal

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

The Journal of urology·2026

Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026

Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026

Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026

Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026

Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026

Related Experiment Videos

Peter E. Clark, MD

Related Concept Videos

Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

Racial and socioeconomic disparities from time of diagnosis to treatment for small renal masses.

Protocol-driven same day discharge for robotic radical prostatectomy.

Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort.

Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.

Reply by Authors.

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

Endourology and Nephrolithiasis.

Related Experiment Videos

Peter E. Clark, MD

Related Concept Videos

Related Articles

Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

Racial and socioeconomic disparities from time of diagnosis to treatment for small renal masses.

Protocol-driven same day discharge for robotic radical prostatectomy.

Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort.

Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.

Reply by Authors.

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

Endourology and Nephrolithiasis.